Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California. Show more

1891 Page Mill Road, Palo Alto, CA, 94304, United States

Biotechnology

Healthcare

Market Cap

431.9M

52 Wk Range

$11.94 - $33.20

Previous Close

$11.99

Open

$11.95

Volume

695,790

Day Range

$11.66 - $12.59

Enterprise Value

232.9M

Cash

211.5M

Avg Qtr Burn

-27.5M

Insider Ownership

3.18%

Institutional Own.

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
EVO756 (MRGPRX2 Antagonist) Details Moderate-To-Severe Atopic Dermatitis	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EVO301 (IL-18 Inhibitor) Details Moderate-To-Severe Atopic Dermatitis	Phase 2b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EVO756 (MRGPRX2 Antagonist) Details Migraine	Phase 2b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EVO756 (MRGPRX2 Antagonist) Details Moderate-To-Severe Chronic Spontaneous Urticaria	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.